TVTX – travere therapeutics, inc. (US:NASDAQ)
Stock Stats
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Piper Sandler from $12.00 to $22.00. They now have a "neutral" rating on the stock.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form SC 13G/A Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Form SC 13G Travere Therapeutics, Filed by: Woodline Partners LP
Form SC 13G/A Travere Therapeutics, Filed by: Deep Track Capital, LP
Form SC 13G/A Travere Therapeutics, Filed by: VANGUARD GROUP INC
Form SC 13G/A Travere Therapeutics, Filed by: MORGAN STANLEY
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.